Skip Navigation


JAC Advance Access originally published online on October 17, 2008
Journal of Antimicrobial Chemotherapy 2008 62(6):1174-1180; doi:10.1093/jac/dkn421
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
62/6/1174    most recent
dkn421v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morello, J.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morello, J.
Right arrow Articles by Soriano, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Reviews

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

Judit Morello1, Sonia Rodríguez-Novoa1,*, Inmaculada Jiménez-Nácher1 and Vincent Soriano2

1 Pharmacy Unit, Hospital Carlos III, Madrid, Spain 2 Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

* Corresponding author. Tel: +34-91-4532694; Fax: +34-91-4532696; E-mail: sonia_r_novoa{at}hotmail.com

Ribavirin in combination with pegylated interferon {alpha} is the current standard treatment for chronic hepatitis C. Adequate exposure to ribavirin seems crucial for achieving the best virological response. However, anaemia is a frequent, dose-dependent limiting side effect of ribavirin use. Therefore, therapeutic drug monitoring of ribavirin plasma concentrations could be a useful tool for individualizing ribavirin dosing. Herein, we review the relationship between ribavirin plasma concentrations and both virological response and toxicity, in order to define an optimal therapeutic range for ribavirin.

Keywords: HCV , HIV , therapeutic drug monitoring , pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. H. Chan, N. Partovi, and M. H. Ensom
The Utility of Therapeutic Drug Monitoring for Ribavirin in Patients with Chronic Hepatitis C--A Critical Review
Ann. Pharmacother., December 1, 2009; 43(12): 2044 - 2063.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.